We collect and use identifiers such as cookies to make it easier for you to use our website and give you a better experience. By using this website, you consent to Organogenesis using website identifiers, including cookies, for these purposes. To read our privacy policy, click here × × A message from our CEO, Gary S. Gillheeney, Sr. on COVID-19. Learn More PATIENTS PROFESSIONALS INVESTORS CAREERS NEWS & EVENTS CONTACT US About Us Advanced Wound Care Surgical & Sports Medicine Circle of Care Program Reimbursement & Regulatory Healing personalized. Joy restored. From advanced wound care through surgery and sports medicine, we are committed to empowering healing by confidently and reliably delivering clinicians the range of regenerative medicine products and services they need. Advanced Wound Care Our products are specially developed for the successful treatment of chronic and acute wounds. Our comprehensive portfolio of skin substitutes and other regenerative medicine products empower our patients with life-changing solutions. Learn More Surgical & Sports Medicine Our surgical & sports medicine products support the healing of musculoskeletal injuries and degenerative conditions. Our strength is giving others strength. Learn More PuraPly® Antimicrobial (PuraPly® AM) Wound Matrix is an FDA 510(k)–cleared Class II medical device that is indicated for the management of a variety of acute and chronic wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, trauma wounds, draining wounds, and first– and second–degree burns. Launched in 2016, PuraPly AM is an essential part of BBWM™, a proactive approach which aims to reduce and manage the reformation of biofilm with sharp debridement and the use of PuraPly AM. Learn More About PuraPly® News & Events October 27, 2021 CANTON, MA. Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Fall 2021 Conference Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and NuShield® product lines will be showcased at the 2021 Symposium on Advanced Wound Care (SAWC) Fall Conference held October 29-31 in Las Vegas, Nev. READ MORE October 7, 2021 CANTON, MA. Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2021 financial results will be reported after the market closes on Tuesday, November 9th. READ MORE May 10, 2021 CANTON, MA. Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three months ended March 31, 2021. READ MORE Load more articles © 2019 Organogenesis Inc. All rights reserved ABOUT US ADVANCED WOUND CARE SURGICAL AND SPORTS MEDICINE CIRCLE OF CARE PROGRAM REIMBURSEMENT AND REGULATORY PATIENTS PROFESSIONALS CAREERS CONTACT US TERMS OF USE PRIVACY POLICY COOKIE POLICY TERMS & CONDITIONS Connect with us